Dania Therapeutics ApS
CVR 42523925 · Private limited company (ApS) · Active · High risk
Dania Therapeutics ApS is a Private limited company (ApS), founded on , based in København K. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 4.5% over the next 12 months, which is 3.2 times the average for Danish companies. 4 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK -15.4m and a net result of DKK -5.0m. CEO: Karin Absalonsen.
Bankruptcy risk for Dania Therapeutics ApS
3.2 × the average (1.41%) · higher risk than 91% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 42523925
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (5 years)
- Address
- c/o Nyborg & Rørdam Advokatfirma P/S, Store Kongensgade 77
1264 København K - Municipality
- København
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 60k
- Auditor
- Grant Thornton, Godkendt Revisionspartnerselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 0 of 4 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -440.1% |
| Current ratio | 425% |
| Moves (last 2 years) | 1 |
| CEO changes in total | 2 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 74 |
| Going-concern uncertainty | Yes |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Revenue | DKK 0 | DKK 0 |
| Gross profit | DKK -3.4m | DKK -8.8m |
| Net profit | DKK -5.0m | DKK -9.6m |
| Equity | DKK -15.4m | DKK -10.4m |
| Total assets | DKK 3.5m | DKK 7.1m |
| Cash | DKK 2.7m | – |
| Short-term debt | DKK 825k | – |
| Avg. employees | 1 | – |
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · Grant Thornton, Godkendt Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 169 | ||
| 1 Jan 2024 – 31 Dec 2024 | 171 | ||
| 1 Jan 2023 – 31 Dec 2023 | 173 | ||
| 1 Jul 2021 – 31 Dec 2022 | 179 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Karin Absalonsen | Current | |
| CEO | Hamed Mozaffari Brodersen | ||
| Board | Karin Absalonsen | Current | |
| Board | Michael Manchuan Li | Current | |
| Board | Kristian Helin | Current | |
| Board | Kristian Helin | ||
| Board | Kim Andersen | ||
| Board | Lars Michael Wood | ||
| Owner (33%) | Kristian Helin | Current | |
| Owner (15%) | Hannibal Innovation ApS | Current | |
| Owner (25%) | Vernalis (R&D) Limited | Current | |
| Owner (5%) | Karl Agger | ||
| Owner (50%) | Kristian Helin | ||
| Owner (5%) | kim Andersen ApS | ||
| Owner (25%) | Hannibal Innovation ApS | ||
| Owner (20%) | Hannibal Innovation ApS | ||
| Owner (5%) | Vernalis (R&D) Limited | ||
| Owner (50%) | Kristian Helin | ||
| Owner (10%) | Vernalis (R&D) Limited | ||
| Owner (15%) | Vernalis (R&D) Limited | ||
| Owner (20%) | Vernalis (R&D) Limited | ||
| Auditor | Grant Thornton, Godkendt Revisionspartnerselskab | Current | |
| Founder | Karl Agger | Current | |
| Founder | Kristian Helin | Current | |
| Founder | kim Andersen ApS | Current | |
| Founder | Hannibal Innovation ApS | Current |
The CEOs' other companies
Karin Absalonsen – 15 other companies
- BARKA Therapeutics ApS Active
- BIO VÆKST ApS Fusioneret
- CARPENTER ApS Active
- CARPENTER HOLDINGS ApS Active
- CELL BIOTECH HOLDING A/S Opløst
- HERON HOLDING A/S Opløst
- Hannibal Innovation ApS Active
- IMMUNITRACK ApS Fusioneret
- Integris Systems ApS Active
- KARAB Holding ApS Active
- KBM ApS Active
- Karab Holding ApS Fusioneret
- MA MANAGEMENT A/S Fusioneret
- NYBORG & RØRDAM ADVOKATKOMPLEMENTARANPARTSSELSKAB Active
- Opportunities and investments ApS Opløst
Hamed Mozaffari Brodersen – 2 other companies
- BARKA Therapeutics ApS Active
- Hannibal Innovation ApS Active
Address history (1 moves)
| c/o Nyborg & Rørdam Advokatfirma P/S, Store Kongensgade 77, 1264 København K | |
| c/o Hannibal Innovation ApS, Sundvænget 36, 2900 Hellerup |
Other companies at the same address
- BOTRIX FINANS ApS Bankrupt
- BOTRIX INTERNATIONAL ApS Bankrupt
- ERHVERVSDIALOG GRUPPEN ApS Bankrupt
- HEINE BØGEBJERG JØRGENSENS FAMILIEFOND Bankrupt
- I&C Denmark ApS Bankrupt
- StampesPlanker ApS Bankrupt
- ADD-VISION ApS Opløst
- ADQUOTA INTERNATIONAL ApS Opløst
- ADVOKATANPARTSSELSKABET ERIK NYBORG Fusioneret
- ADVOKATANPARTSSELSKABET JOHN HAVE Opløst
- ADVOKATANPARTSSELSKABET THOMAS RØRDAM Opløst
- ADVOKATANPARTSSELSKABET AF 30.12.1993 Fusioneret
- ADVOKATANPARTSSELSKABET AF 30/11 2004 Opløst
- ADVOKATANPARTSSELSKABET HANNE RAHBÆK Active
- ADVOKATANPARTSSELSKABET HENRIK FÜRSTENBERG Active
- ADVOKATANPARTSSELSKABET MARYLA RYTTER WRÓBLEWSKI Active
- AFVIKLINGSSELSKABET AF 14. JANUAR 2000 A/S Opløst
- AHLBLAD ARKITEKTER & INGENIØRER ApS Active
- AHLBLAD HOLDING ApS Active
- AS-ANT Holding ApS Active
- ATLANTIC CORPORATE FINANCE A/S Compulsorily dissolved
- Advokatanpartsselskabet SP4 Active
- Advokatanpartsselskabet af 01.09.2012 Active
- Advokatanpartsselskabet af 30.12.1993 Active
- Advokatanpartsselskabet af 30.12.2005 Fusioneret
Similar companies in København
- CARLSBERG A/S København V
- CuraVision ApS København V
- Launch Bioindustries ApS København Ø
- RheumaLogics ApS København Ø
- Vitibiotech ApS København N
- Pyovita ApS Hellerup
- ArcanaBio ApS København N
- OvartiX ApS København N
- Keystone Consulting ApS København SV
- KPL ApS København N
- Alveus Therapeutics ApS København K
- Cambiotics ApS København N
Questions and answers about Dania Therapeutics ApS
Has Dania Therapeutics ApS gone bankrupt?
No, Dania Therapeutics ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Dania Therapeutics ApS?
Our model estimates a bankruptcy risk of 4.5% over the next 12 months (high risk), which is 3.2 times the average for Danish companies.
Who is the CEO of Dania Therapeutics ApS?
Karin Absalonsen is the CEO of Dania Therapeutics ApS.
Who is the auditor of Dania Therapeutics ApS?
Dania Therapeutics ApS most recently used Grant Thornton, Godkendt Revisionspartnerselskab.
When was Dania Therapeutics ApS founded?
Dania Therapeutics ApS was founded on 1 July 2021.
What is the equity of Dania Therapeutics ApS?
Equity was DKK -15.4m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.